Tue Apr 13, 2010 8:59pm IST
By Katie Reid and Ben Hirschler
ZURICH/LONDON (Reuters) - Recent setbacks mean the high-water mark for Avastin revenues will be lower than some investors had hoped, but Roche's cancer blockbuster remains on track to become the world's top-selling medicine.
Avastin, which starves tumours of blood supply, is a key weapon in the fight against colon, lung, breast and other cancers -- and Roche's biggest drug.
Phase-3 results from the AVOREN trial showed that the combination of bevacizumab and interferon alfa-2a improved OS as first-line therapy in patients with metastatic renal cell carcinoma.
These results update findings presented at the 2007 and 2008 ASCO Annual Meetings detailing the safety of the combination and its beneficial effect on PFS.
From June 2004 to October 2005, researchers randomly assigned 649 previously...
Rosetta Genomics Now Processing Fine-Needle Aspirate Cell Block Samples for Lung Cancer Subclassification
April 05, 2010 07:30 AM Eastern Daylight Time
Molecular test that helps determine treatment can now be performed before the tumor is surgically resected
Uses highly accurate microRNA-based technology of miRview™ squamous test on Fine-Needle Aspirate (FNA) cell block samples to subclassify non-small cell lung cancer (NSCLC)
Bevacizumab/Paclitaxel/Carboplatin Will Remain Decision Resources' Proprietary Clinical Gold Standard for the Treatment of Advanced Non-Small-Cell Lung Cancer
A Drug's Effect on Overall Survival is the Attribute that Most Influences Surveyed Oncologists' Prescribing Decisions in Advanced Non-Small-Cell Lung Cancer, According to a New Report from Decision Resources
WALTHAM, Mass., March 23 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory...
